Synergistic activity between beta-lactams and igy antibodies against Pseudomonas aeruginosa in vitro

Sanches, Renata Fernandes; Ferraro, Ana Carolina Navarro dos Santos; Carrara-Marroni, Floristher Elaine; Venâncio, Emerson José

doi:10.1016/j.molimm.2022.05.010

Cited by 8 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believed that clindamycin-other antibiotics would inhibit bacterial well. The synthesized compound might have certain antibacterial activity for Gram-positive bacteria, (Kurtul et al, 2022) fungi, (Sanches et al, 2022), and Gram-negative bacteria.…”

Section: Antibacterial Activitymentioning

confidence: 99%

“…After insights are gained into the inherent properties, action mechanism (Wakiyama et al, 2018) and SAR of clindamycin (Kurtul et al, 2022; Yao et al, 2016; Zhang et al, 2022). This study suggested employing pharmaceutical modifications and the binding of pharmacophores to each other (Sanches et al, 2022) to broaden its bacteriostatic range.…”

Section: Introductionmentioning

confidence: 99%

“…The principle of molecular resonance is a design concept of heterozygous drugs. This implies that, in cases where the targets of designed polyheterozygous drugs are situated nearby, they will engage in homodimerization or heterodimerization after activation by the multi‐target drug, exemplified by instances involving steroids and HIV protease receptors (Sanches et al, 2022). However, when the targets of the two pharmacophores are far apart, the two pharmacophores can act separately, but ensure that the combined inhibitory fraction is ≤2.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Design, synthesis, and bioactivity evaluation of clindamycin derivatives against multidrug‐resistant bacterial strains

Jia,

Zhang,

Zhu

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

Our research aims to reduce the bacterial resistance of clindamycin against Gram‐positive bacteria and expand its range of bacterial susceptibility. First, we optimized the structure of clindamycin based on its structure–activity relationship. Second, we employed the fractional inhibitory concentration method to detect drugs suitable for combination with clindamycin derivatives. We then used a linker to connect the clindamycin derivatives with the identified combined therapy drugs. Finally, we tested antibacterial susceptibility testing and conducted in vitro bacterial inhibition activity assays to determine the compounds. with the highest efficacy. The results of our study show that we synthesized clindamycin propionate derivatives and clindamycin homo/heterodimer derivatives, which exhibited superior antibacterial activity compared to clindamycin and other antibiotics against both bacteria and fungi. In vitro bacteriostatic activity testing against four types of Gram‐negative bacteria and one type of fungi revealed that all synthesized compounds had bacteriostatic effects at least 1000 times better than clindamycin and sulfonamides. The minimum inhibitory concentration (MIC) values for these compounds ranged from 0.25 to 0.0325 mM. Significantly, compound 5a demonstrated the most potent inhibitory activity against three distinct bacterial strains, displaying MIC values spanning from 0.0625 to 0.0325 mM. Furthermore, our calculations indicate that compound 5a is safe for cellular use. In conclusion, the synthesized compounds hold great promise in addressing bacterial antibiotic resistance.

show abstract

Section: Antibacterial Activitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Design, synthesis, and bioactivity evaluation of clindamycin derivatives against multidrug‐resistant bacterial strains

Jia,

Zhang,

Zhu

et al. 2024

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…This Anti-PcrV IgY augmented opsonophagocytic killing and repressed bacterial invasion in P. aeruginosa murine acute pneumonia and burn wound models [ 148 ]. A synergistic action between anti- P. aeruginosa IgY and beta-lactams (ceftazidime, imipenem, and meropenem) has been recently unveiled and raises the possibility to combine antibodies and antibiotics for treatment of infections by multi-drug resistant P. aeruginosa [ 149 ].…”

Section: Main Textmentioning

confidence: 99%

Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections

et al. 2023

View full text Add to dashboard Cite

The opportunistic human pathogen Pseudomonas aeruginosa is the causal agent of a wide variety of infections. This non-fermentative Gram-negative bacillus can colonize zones where the skin barrier is weakened, such as wounds or burns. It also causes infections of the urinary tract, respiratory system or bloodstream. P. aeruginosa infections are common in hospitalized patients for which multidrug-resistant, respectively extensively drug-resistant isolates can be a strong contributor to a high rate of in-hospital mortality. Moreover, chronic respiratory system infections of cystic fibrosis patients are especially concerning, since very tedious to treat. P. aeruginosa exploits diverse cell-associated and secreted virulence factors, which play essential roles in its pathogenesis. Those factors encompass carbohydrate-binding proteins, quorum sensing that monitor the production of extracellular products, genes conferring extensive drug resistance, and a secretion system to deliver effectors to kill competitors or subvert host essential functions. In this article, we highlight recent advances in the understanding of P. aeruginosa pathogenicity and virulence as well as efforts for the identification of new drug targets and the development of new therapeutic strategies against P. aeruginosa infections. These recent advances provide innovative and promising strategies to circumvent infection caused by this important human pathogen.

show abstract

“…In addition, azithromycin combined with IgY enhances the reduction in pulmonary inflammation ( 53 ). In the in vitro research conducted by Sanches et al., IgY specific to P. aeruginosa (0.625–2.5 mg/ml) revealed synergistic antimicrobial action with beta-lactams: ceftazidime, imipenem, and meropenem ( 51 ). Anti- Pseudomonas IgY were also evaluated against P. aeruginosa –resistive urinary tract infections.…”

Section: Pseudomonas Aeruginosamentioning

confidence: 99%

IgYs: on her majesty’s secret service

2023

View full text Add to dashboard Cite

There has been an increasing interest in using Immunoglobulin Y (IgY) antibodies as an alternative to “classical” antimicrobials. Unlike traditional antibiotics, they can be utilized on a continual basis without leading to the development of resistance. The veterinary IgY antibody market is growing because of the demand for minimal antibiotic use in animal production. IgY antibodies are not as strong as antibiotics for treating infections, but they work well as preventative agents and are natural, nontoxic, and easy to produce. They can be administered orally and are well tolerated, even by young animals. Unlike antibiotics, oral IgY supplements support the microbiome that plays a vital role in maintaining overall health, including immune system function. IgY formulations can be delivered as egg yolk powder and do not require extensive purification. Lipids in IgY supplements improve antibody stability in the digestive tract. Given this, using IgY antibodies as an alternative to antimicrobials has garnered interest. In this review, we will examine their antibacterial potential.

show abstract

Synergistic activity between beta-lactams and igy antibodies against Pseudomonas aeruginosa in vitro

Cited by 8 publications

References 29 publications

Design, synthesis, and bioactivity evaluation of clindamycin derivatives against multidrug‐resistant bacterial strains

Design, synthesis, and bioactivity evaluation of clindamycin derivatives against multidrug‐resistant bacterial strains

Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections

IgYs: on her majesty’s secret service

Contact Info

Product

Resources

About